Neuregen Therapeutics was founded in December 2021 as a biotechnology company dedicated to developing novel gene therapies based on its proprietary cell transdifferentiation technology. The company was co founded by several neuroscientists, ophthalmology experts, gene therapy specialists, and seasoned professionals from the biopharmaceutical industry. It is committed to transforming its emerging in situ transdifferentiation technology into innovative drugs and solutions that address unmet clinical needs.

The current pipeline focuses on tumors and degenerative diseases of the nervous system, with an emphasis on developing first in class therapeutics for blinding ocular diseases, other degenerative disorders, and hard to treat central nervous system (CNS) tumors.